Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / Prostate and Urologic Cancers Research Group / Completed validation of %[-2]proPSA to improve PSA-based detection of prostate cancer; IVD FDA approved

Completed validation of %[-2]proPSA to improve PSA-based detection of prostate cancer; IVD FDA approved

Click here to view more information in the biomarker database for proPSA

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.